SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Serono successfull competitor to Biogen
An SI Board Since June 2002
Posts SubjectMarks Bans Symbol
10 3 0 SRA
Emcee:  Alfred W. Post Type:  Unmoderated
Introduction Market Data Compact
One of the world's top biotechs, Serono focuses on recombinant genetic engineering to develop drugs. With operations in 45 countries ranging from marketing to manufacturing to research and development, the Swiss firm is a leader in reproductive health; flagship drug Gonal-F accounts for 30% of Serono's sales. The firm also focuses on neurological, metabolic, and human growth disorders. Other recombinant products include treatments for multiple sclerosis (Rebif, more than a quarter of sales), growth hormone deficiency, and AIDS-related wasting. With Rebif's approval for MS in the US, Serono hopes to claim market share from leader Biogen.
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
10Signals overviews Serono and its alliances: signalsmag.com Cheers, Tucktuck-5/25/2005
9Shares in Elan and Biogen Idec plunge as the firms suspend sales of multiple sclAlfred W. Post-3/1/2005
8Serono and Amgen Sign License Agreement for Multiple Sclerosis Product November Alfred W. Post-11/13/2002
7Serono gets $200 mio from Pfizer who shows interest in the merits of the multiplAlfred W. Post-7/11/2002
6Duke something went wrong. see for yourself, your message got lost. But in the mAlfred W. Post-6/9/2002
5In my opinion the recovery chances for Serono have greatly improved since the coAlfred W. Post-6/9/2002
4<i>The Duke of URL©-6/9/2002
3Hi Duke, now you do if you read the addition to my original text. I got his infoAlfred W. Post-6/9/2002
2Biogen vs. Serono (this actually is the end of my introduction of Serono, but thAlfred W. Post-6/9/2002
1<i> Serono successfull competitor to Biogen</i> I didn't even kThe Duke of URL©-6/9/2002
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News